Tivozanib in renal cell carcinoma: a new approach to previously treated disease

Targeted therapies have been a mainstay of the renal cell carcinoma (RCC) treatment paradigm for the better part of two decades. Multikinase inhibitors of the vascular endothelial growth factor receptor tyrosine kinases (VEGF-TKIs) comprise nearly all targeted therapies in RCC, having been prospecti...

Descripción completa

Detalles Bibliográficos
Autores principales: Salgia, Nicholas J., Zengin, Zeynep B., Pal, Sumanta K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Challenging Dogma: New Evidence to Guide Practice in Urologic Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7249546/
https://www.ncbi.nlm.nih.gov/pubmed/32547647
http://dx.doi.org/10.1177/1758835920923818

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7249546/
https://www.ncbi.nlm.nih.gov/pubmed/32547647
http://dx.doi.org/10.1177/1758835920923818

Ejemplares similares